Immunohistochemistry was used to examine GPX4 expression in samples from 93 DLBCL patients, and the GPX4 positive group (35%) had significantly lower overall and progression-free survival rates [79]. The gene discussed is GPX4; the disease is diffuse large B-cell lymphoma.